Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome

Objectives: The aim of this study was to analyze the clinical efficacy and cytomorphologic changes of colon mucosa following the treatment of patients suffering from irritable bowel syndrome (IBS) with mesalazine (5-aminosalicylic acid [5-ASA]). Methods: In this controlled, randomized, blind clinical trial, a total of 360 patients with varying subtypes of IBS were randomly treated with 500 mg of mesalazine qid or by standard therapy without mesalazine for a period of 28 days. Pre- and post-treatment pain intensity, pain duration, meteorism, stool abnormalities and endoscopic parameters were monitored, and biopsies or brush biopsies were examined histologically. Results: Treatment of IBS patients with mesalazine significantly reduced intensity and duration of pain in all subtypes of IBS, except for duration of pain in the subtype “undifferentiated”, where the difference was not significant. In addition, in patients with diarrhea type and undifferentiated type of IBS, mesalazine also significantly reduced the abnormal stool pattern. In comparison to the control group, administration of mesalazine reduced the incidence of endoscopic and cytomorphologic changes of the bowel mucosa, including changes in colon mucus, mucus production, cytologic or histologic parameters, epithelial cell degeneration, appearance of leukocytes and macrophages and cell infiltrations. Conclusion: Mesalazine was effective in reducing several symptoms characteristic of IBS. It significantly reduced pain intensity and duration and improved cytohistologic parameters of the bowel mucosa.

[1]  G. Boeckxstaens,et al.  The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome , 2010, Gut.

[2]  G. Barbara,et al.  Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome , 2010, Digestive Diseases.

[3]  W. Chey,et al.  Evaluation of Patient-Reported Outcomes in Irritable Bowel yndrome Randomized Controlled Trials : A Rome Foundation Report , 2022 .

[4]  G. Barbara,et al.  Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof‐of‐concept study , 2009, Alimentary pharmacology & therapeutics.

[5]  G. Barbara,et al.  What is the effect of inflammation on intestinal function? , 2008, Inflammatory bowel diseases.

[6]  Hinrich W. H. Göhlmann,et al.  Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  T. Dinan,et al.  Mucosal cytokine imbalance in irritable bowel syndrome , 2008, Scandinavian journal of gastroenterology.

[8]  M. Camilleri,et al.  Symptomatic overlap between irritable bowel syndrome and microscopic colitis. , 2011, Inflammatory bowel diseases.

[9]  M. Steinhoff,et al.  Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.

[10]  A. Forbes,et al.  European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.

[11]  F. Shanahan,et al.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.

[12]  G. Barbara,et al.  New pathophysiological mechanisms in irritable bowel syndrome , 2004, Alimentary pharmacology & therapeutics.

[13]  D. Santini,et al.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.

[14]  K. Olden,et al.  Psychosocial aspects of functional gastrointestinal disorders. , 2003, Gastroenterology clinics of North America.

[15]  B. Vogt,et al.  Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. , 2003, Gastroenterology.

[16]  R. Spiller.  Postinfectious irritable bowel syndrome. , 2003, Gastroenterology.

[17]  D. Drossman,et al.  AGA technical review on irritable bowel syndrome. , 2002, Gastroenterology.

[18]  E. Björnsson,et al.  Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors , 2002, American Journal of Gastroenterology.

[19]  Robin C. Spiller,et al.  Rome II: the Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: a Multinational Consensus , 2000 .

[20]  R. Kessler,et al.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. , 2000, Gastroenterology.

[21]  W. Paterson,et al.  Predictive value of the rome criteria for diagnosing the irritable bowel syndrome , 1999, American Journal of Gastroenterology.

[22]  E A Mayer,et al.  Basic and clinical aspects of visceral hyperalgesia. , 1994, Gastroenterology.

[23]  R. Clouse,et al.  Pericrypt eosinophilic enterocolitis and chronic diarrhea. , 1992, Gastroenterology.

[24]  W. Paulus,et al.  A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. , 1984, Gastroenterology.

[25]  P. Whorwell,et al.  Symptoms of irritable bowel syndrome in ulcerative colitis in remission , 1983, Gut.

[26]  P. Openshaw,et al.  Towards positive diagnosis of the irritable bowel. , 1978, British medical journal.

[27]  M. Hirvonen.  [Intestinal diseases]. , 1954, Suomen laakarilehti. Finlands lakartidning.